S.Res. 620: A resolution designating February 28, 2026, as "Rare Disease Day".
Sponsor
John Barrasso
Republican · WY
Bill Progress
Latest Action · Feb 26, 2026
Passed the Senate, received in House
Why it matters
The resolution lands as millions of Americans with rare diseases still face delayed diagnoses, high treatment costs, and too few approved therapies.
This is a simple, symbolic Senate resolution, but its message is broad and timely. It says rare diseases may affect small numbers of people one by one, yet together they touch more than 30 million people in the United States. The resolution highlights a basic problem: most rare diseases still have no FDA-approved treatment, even after years of scientific progress.
The measure also lays out the real-world barriers patients face. People with rare diseases often struggle to get an accurate diagnosis, find doctors with the right expertise, and pay for treatments that can be life-changing or life-saving. It especially notes that children make up a significant share of those affected, underscoring the long-term burden on families.
The resolution ties today’s challenges to the broader policy framework already in place. It points to the Orphan Drug Act, now 43 years old, as a key reason rare disease research and drug development have advanced. It also recognizes work by the National Institutes of Health and an FDA program aimed at speeding up cures and improving the path for rare disease treatments.
In practical terms, this resolution is more about awareness than action. It does not change the law, require agencies to do anything new, or provide money. But it gives senators a public way to endorse earlier diagnosis, stronger research, and continued attention to a patient community that often feels invisible.
What does S.Res. 620 do?
Names February 28 as Rare Disease Day
Officially designates February 28, 2026, as "Rare Disease Day" in the Senate.
Calls for more public awareness
Recognizes the importance of helping more people understand rare diseases and disorders.
Pushes earlier and more accurate diagnosis
Highlights the need to improve diagnosis so patients can be identified sooner and more accurately.
Supports research for treatments and cures
Backs national and global research efforts to develop better treatments, diagnostics, and cures.
Highlights the treatment gap
Points out that about 95 percent of rare diseases still do not have an FDA-approved treatment.
Recognizes existing rare disease efforts
Acknowledges the role of the Orphan Drug Act, NIH research, and FDA rare disease programs in advancing care and drug development.
Who benefits from S.Res. 620?
People living with rare diseases
They gain national visibility for the challenges they face, including missed diagnoses and lack of treatment options.
Families and caregivers
The resolution validates the financial and emotional strain families often carry while seeking care and treatment.
Rare disease researchers and advocacy groups
They get a public boost for awareness campaigns and for pushing continued research into diagnostics, treatments, and cures.
Children with rare diseases
The measure draws attention to a group that makes up a significant share of rare disease patients and often needs long-term support.
Who is affected by S.Res. 620?
Patients seeking a diagnosis
The resolution highlights how hard it can be to get an accurate diagnosis and find specialists with the right expertise.
Doctors and specialty treatment centers
It adds pressure and public attention around improving recognition of rare diseases and connecting patients to expert care.
Federal health agencies like NIH and FDA
Their current work on rare disease research and treatment development is recognized and put in the spotlight.
Drug developers working on orphan drugs
The resolution reinforces public support for continued development of medicines for small patient populations.
SRES620 Legislative Journey
Floor Action
Feb 26, 2026
Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S716; text: CR S711)
About the Sponsor
John Barrasso
Republican, WY · 19 years in Congress
Committees: Energy and Natural Resources, Foreign Relations, Finance
View full profile →
Cosponsors (5)
This bill has 5 cosponsors: 3 Democrats, 2 Republicans, reflecting bipartisan support. Cosponsors represent 5 states: Connecticut, Kansas, Minnesota, and 2 more.
S.Res. 620 Quick Facts
- Chamber
- Senate
- Policy
- Health
- Introduced
- Feb 26, 2026
Passed the Senate, received in House
Feb 26, 2026
S.Res. 620 Bill Text
“Designating February 28, 2026, as “Rare Disease Day”.”
Source: U.S. Government Publishing Office
Get notified when S.Res. 620 moves
Committee votes, floor action, cosponsor changes — straight to your inbox.
Bill alerts + Legisletter's monthly briefing. Unsubscribe anytime.
Health Bills
9 related bills we're tracking
Give Kids a Chance Act of 2025
Motion to reconsider laid on the table Agreed to without objection.
Dec 1, 2025
Improving Seniors’ Timely Access to Care Act of 2025
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 20, 2025
CONNECT for Health Act of 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jun 26, 2025
Right to Contraception Act
Referred to the House Committee on Energy and Commerce.
Feb 5, 2025
Medicare Patient Access and Practice Stabilization Act of 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jan 31, 2025
Chiropractic Medicare Coverage Modernization Act of 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jan 16, 2025
988 LGBTQ+ Youth Access Act of 2025
Referred to the House Committee on Energy and Commerce.
Sep 17, 2025
Ensuring Lasting Smiles Act
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 8, 2025
Pride In Mental Health Act of 2025
Referred to the House Committee on Energy and Commerce.
Jun 5, 2025
Trending Right Now
Bills gaining momentum across Congress
Healthy Families Act
Referred to the Committee on Education and Workforce, and in addition to the Committees on House Administration, and Oversight and Government Reform, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Feb 12, 2026
Federal Extreme Risk Protection Order Act of 2026
Referred to the House Committee on the Judiciary.
Feb 17, 2026
ALERT Act
Referred to the Committee on Transportation and Infrastructure, and in addition to the Committee on Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Feb 20, 2026
Tracking Health in Congress? Monitor bills, track cosponsor momentum, and launch advocacy campaigns — all from one advocacy platform.